Istituto di Ricerca Pediatrica Città della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy.
Medicina (Kaunas). 2023 Sep 27;59(10):1722. doi: 10.3390/medicina59101722.
Mass spectrometry-based proteomics is a key player in research efforts to characterize aberrant epigenetic alterations, including histone post-translational modifications and DNA methylation. Data generated by this approach complements and enrich datasets generated by genomic, epigenetic and transcriptomics approaches. These combined datasets can provide much-needed information on various mechanisms responsible for drug resistance, the discovery and validation of potential biomarkers for different diseases, the identification of signaling pathways, and genes and enzymes to be targeted by future therapies. The increasing use of high-resolution, high-accuracy mass spectrometers combined with more refined protein labeling and enrichment procedures enhanced the role of this approach in the investigation of these epigenetic modifications. In this review, we discuss recent MS-based studies, which are contributing to current research efforts to understand certain mechanisms behind drug resistance to therapy. We also discuss how these MS-based analyses are contributing to biomarkers discovery and validation.
基于质谱的蛋白质组学是研究特征性表观遗传改变（包括组蛋白翻译后修饰和 DNA 甲基化）的重要手段。该方法产生的数据补充和丰富了基因组、表观遗传学和转录组学方法产生的数据。这些综合数据集可以提供对各种耐药机制、不同疾病潜在生物标志物的发现和验证、信号通路以及未来治疗的靶向基因和酶的急需信息。高分辨率、高精度质谱仪的日益使用，结合更精细的蛋白质标记和富集程序，增强了该方法在研究这些表观遗传修饰中的作用。在这篇综述中，我们讨论了最近基于 MS 的研究，这些研究有助于当前对治疗耐药背后某些机制的研究。我们还讨论了基于 MS 的这些分析如何有助于生物标志物的发现和验证。
